Which has higher valuation & earnings, ROIV or TGTX?

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $8.26M 2,952.84 -$299.77M -$0.60 N/A TG Therapeutics $616.29M 12.92 $447.18M $2.86 18.19

Does the media prefer ROIV or TGTX?

In the previous week, Roivant Sciences had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Roivant Sciences and 6 mentions for TG Therapeutics. Roivant Sciences' average media sentiment score of 1.16 beat TG Therapeutics' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, INSM or TGTX?

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.24 -$1.28B -$5.75 N/A TG Therapeutics $616.29M 12.92 $447.18M $2.86 18.19

Is INSM or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer INSM or TGTX?

In the previous week, Insmed had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.30 beat TG Therapeutics' score of 0.97 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or TGTX?

In the previous week, BioNTech and BioNTech both had 6 articles in the media. TG Therapeutics' average media sentiment score of 0.97 beat BioNTech's score of 0.86 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TGTX or MRNA more profitable?

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -141.43%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 65.95% 88.73% 43.44% Moderna -141.43% -28.30% -19.39%

Does the media favor TGTX or MRNA?

In the previous week, Moderna had 40 more articles in the media than TG Therapeutics. MarketBeat recorded 46 mentions for Moderna and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat Moderna's score of 0.38 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 15 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral

Is VTRS or TGTX more profitable?

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% TG Therapeutics 65.95% 88.73% 43.44%

Does the media prefer VTRS or TGTX?

In the previous week, TG Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 6 mentions for TG Therapeutics and 5 mentions for Viatris. TG Therapeutics' average media sentiment score of 0.97 beat Viatris' score of 0.39 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TG Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Live Earnings Conference Call: TG Therapeutics will host a live Q2 2026 earnings call on August 3, 2026 at 8:30AM ET. Get details.

TG Therapeutics (TGTX) Competitors

$52.03 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$52.13 +0.10 (+0.18%)

As of 07/31/2026 07:59 PM Eastern

Compare

TGTX vs. ROIV, INSM, BNTX, MRNA, and VTRS

Should you buy TG Therapeutics stock or one of its competitors? MarketBeat compares TG Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TG Therapeutics include Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), Moderna (MRNA), and Viatris (VTRS).

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TG Therapeutics has a net margin of 65.95% compared to Roivant Sciences' net margin of -3,629.19%. TG Therapeutics' return on equity of 88.73% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,952.84	-$299.77M	-$0.60	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Roivant Sciences presently has a consensus target price of $33.59, suggesting a potential downside of 0.94%. TG Therapeutics has a consensus target price of $58.50, suggesting a potential upside of 12.44%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, Roivant Sciences had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 16 mentions for Roivant Sciences and 6 mentions for TG Therapeutics. Roivant Sciences' average media sentiment score of 1.16 beat TG Therapeutics' score of 0.97 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Roivant Sciences on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

TG Therapeutics has a net margin of 65.95% compared to Insmed's net margin of -144.44%. TG Therapeutics' return on equity of 88.73% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
TG Therapeutics	65.95%	88.73%	43.44%

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

Insmed has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

Insmed currently has a consensus price target of $209.35, indicating a potential upside of 112.32%. TG Therapeutics has a consensus price target of $58.50, indicating a potential upside of 12.44%. Given Insmed's stronger consensus rating and higher probable upside, equities analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

58.6% of TG Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Insmed had 7 more articles in the media than TG Therapeutics. MarketBeat recorded 13 mentions for Insmed and 6 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.30 beat TG Therapeutics' score of 0.97 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

TG Therapeutics beats Insmed on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

TG Therapeutics has a net margin of 65.95% compared to BioNTech's net margin of -44.39%. TG Therapeutics' return on equity of 88.73% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
TG Therapeutics	65.95%	88.73%	43.44%

BioNTech currently has a consensus price target of $129.13, suggesting a potential upside of 42.55%. TG Therapeutics has a consensus price target of $58.50, suggesting a potential upside of 12.44%. Given BioNTech's stronger consensus rating and higher probable upside, analysts clearly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, BioNTech and BioNTech both had 6 articles in the media. TG Therapeutics' average media sentiment score of 0.97 beat BioNTech's score of 0.86 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

15.5% of BioNTech shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 19.2% of BioNTech shares are held by company insiders. Comparatively, 8.9% of TG Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BioNTech has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market.

TG Therapeutics has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

Summary

TG Therapeutics beats BioNTech on 10 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Moderna?

TG Therapeutics (NASDAQ:TGTX) and Moderna (NASDAQ:MRNA) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

TG Therapeutics has a net margin of 65.95% compared to Moderna's net margin of -141.43%. TG Therapeutics' return on equity of 88.73% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	65.95%	88.73%	43.44%
Moderna	-141.43%	-28.30%	-19.39%

TG Therapeutics has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19
Moderna	$1.94B	11.19	-$2.82B	-$8.15	N/A

In the previous week, Moderna had 40 more articles in the media than TG Therapeutics. MarketBeat recorded 46 mentions for Moderna and 6 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.97 beat Moderna's score of 0.38 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	15 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral

TG Therapeutics has a beta of 1.62, suggesting that its share price is 62% more volatile than the broader market. Comparatively, Moderna has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics currently has a consensus target price of $58.50, suggesting a potential upside of 12.44%. Moderna has a consensus target price of $40.00, suggesting a potential downside of 27.03%. Given TG Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82

Summary

TG Therapeutics beats Moderna on 12 of the 16 factors compared between the two stocks.

How does TG Therapeutics compare to Viatris?

Viatris (NASDAQ:VTRS) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market.

TG Therapeutics has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.43	-$3.51B	-$0.26	N/A
TG Therapeutics	$616.29M	12.92	$447.18M	$2.86	18.19

79.9% of Viatris shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 0.3% of Viatris shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, TG Therapeutics had 1 more articles in the media than Viatris. MarketBeat recorded 6 mentions for TG Therapeutics and 5 mentions for Viatris. TG Therapeutics' average media sentiment score of 0.97 beat Viatris' score of 0.39 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TG Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Viatris currently has a consensus price target of $17.50, suggesting a potential downside of 0.34%. TG Therapeutics has a consensus price target of $58.50, suggesting a potential upside of 12.44%. Given TG Therapeutics' higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has a net margin of 65.95% compared to Viatris' net margin of -2.04%. TG Therapeutics' return on equity of 88.73% beat Viatris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
TG Therapeutics	65.95%	88.73%	43.44%

Summary

TG Therapeutics beats Viatris on 13 of the 16 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.96B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	18.19	7.38	282.27	24.66
Price / Sales	12.92	1,273.79	590.91	92.54
Price / Cash	18.57	44.80	28.60	46.71
Price / Book	12.75	16.78	10.93	6.07
Net Income	$447.18M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-6.67%	-1.82%	-0.64%	-0.42%
1 Month Performance	-2.40%	-8.45%	-3.78%	-4.80%
1 Year Performance	48.57%	48.33%	61.99%	18.61%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	3.147 of 5 stars	$52.03 flat	$58.50 +12.4%	+48.6%	$7.96B	$616.29M	18.19	290	Gap Up
ROIV Roivant Sciences	1.5764 of 5 stars	$34.72 -0.8%	$33.59 -3.3%	+199.8%	$25.18B	$8.26M	N/A	860	Positive News Upcoming Earnings Analyst Forecast
INSM Insmed	3.8307 of 5 stars	$104.73 -2.0%	$209.13 +99.7%	-9.3%	$23.18B	$606.42M	N/A	1,664	Positive News Upcoming Earnings Gap Up
BNTX BioNTech	3.9423 of 5 stars	$91.09 +2.0%	$129.13 +41.8%	-15.6%	$22.59B	$3.25B	N/A	7,807	Upcoming Earnings Gap Up
MRNA Moderna	1.3283 of 5 stars	$55.63 +2.9%	$40.00 -28.1%	+98.6%	$21.45B	$1.94B	N/A	4,700	Trending News Earnings Report Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. ROIV, INSM, BNTX, MRNA, and VTRS

How does TG Therapeutics compare to Roivant Sciences?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Moderna?

Summary

How does TG Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. ROIV, INSM, BNTX, MRNA, and VTRS

How does TG Therapeutics compare to Roivant Sciences?

Do institutionals & insiders have more ownership in ROIV or TGTX?

Is ROIV or TGTX more profitable?

Which has higher valuation & earnings, ROIV or TGTX?

Which has more volatility & risk, ROIV or TGTX?

Do analysts rate ROIV or TGTX?

Does the media prefer ROIV or TGTX?

Summary

How does TG Therapeutics compare to Insmed?

Is INSM or TGTX more profitable?

Which has preferable earnings & valuation, INSM or TGTX?

Which has more volatility and risk, INSM or TGTX?

Do analysts rate INSM or TGTX?

Do insiders and institutionals believe in INSM or TGTX?

Does the media prefer INSM or TGTX?

Summary

How does TG Therapeutics compare to BioNTech?

Is BNTX or TGTX more profitable?

Do analysts rate BNTX or TGTX?

Does the media refer more to BNTX or TGTX?

Do insiders & institutionals hold more shares of BNTX or TGTX?

Which has more volatility & risk, BNTX or TGTX?

Which has preferable valuation & earnings, BNTX or TGTX?

Summary

How does TG Therapeutics compare to Moderna?

Is TGTX or MRNA more profitable?

Which has preferable earnings & valuation, TGTX or MRNA?

Does the media favor TGTX or MRNA?

Which has more volatility & risk, TGTX or MRNA?

Do insiders and institutionals hold more shares of TGTX or MRNA?

Do analysts prefer TGTX or MRNA?

Summary

How does TG Therapeutics compare to Viatris?

Which has more risk and volatility, VTRS or TGTX?

Which has higher earnings & valuation, VTRS or TGTX?

Do institutionals & insiders have more ownership in VTRS or TGTX?

Does the media prefer VTRS or TGTX?

Do analysts prefer VTRS or TGTX?

Is VTRS or TGTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools